Date: 2017-01-09
Type of information: Development agreement
Compound: bacteriophage-based treatments
Company: Ferring Pharmaceuticals (Switzerland) Intralytix (USA - MA)
Therapeutic area: Gastrointestinal diseases - Digestive diseases - Infectious diseases
Type agreement: development - commercialisation
Action mechanism: bacteriophage
Disease: conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome
Details:
- • On January 9, 2017, Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.
- Ferring announced an initial collaboration withIntralytix on a bacteriophage-based therapy for inflammatory bowel disease (IBD) in July 2015. By broadening the collaboration, Ferring and Intralytix will now jointly investigate bacteriophage-based drugs to regulate the microbiome of the female reproductive tract, oral cavity, and skin, in addition to the gut.
Financial terms:
Latest news:
Is general: Yes
